phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Study Identifies Potential RAS Inhibitor-Immunotherapy Strategy for Pancreatic Cancer

This study co-led by Dana-Farber Cancer Institute suggests that long-lasting durable remissions for patients with pancreatic cancer might be possible with a novel combination of immunotherapy and RAS-targeted therapy. Immunotherapies typically focus on the activation of cytotoxic CD8 T cells, but this study suggests that tumor-specific CD4 T cells could control pancreatic cancer by coordinating innate immune cells against the disease when stimulated through IL-21 signaling alongside treatment with a KRAS inhibitor.

September 23, 2026


September 23 2026

September 22 2026

September 21 2026

September 18 2026

September 17 2026

September 16 2026

September 15 2026

September 14 2026

September 11 2026

September 10 2026

September 9 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy